Ron Aoyama

A Refined 3-Dimensional QSAR of Cytochrome P450 2C9:  Computational Predictions of Drug Interactions

Sreedhara V. Rao, Ron Aoyama, Michael Schrag et al. · Journal of Medicinal Chemistry · 2000 · 91 citations · Full text

Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor

Harvey Wong, Laurent Vernillet, Amy Peterson et al. · Clinical Cancer Research · 2012 · 79 citations

Discovery of a Novel Class of Highly Potent, Selective, ATP-Competitive, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin (mTOR)

Craig S. Takeuchi, Byung Gyu Kim, Charles M. Blazey et al. · Journal of Medicinal Chemistry · 2013 · 65 citations · Full text

Compound 28, Drug Target, Pharmacotherapy +20

Preclinical Disposition of GDC-0973 and Prospective and Retrospective Analysis of Human Dose and Efficacy Predictions

Edna F. Choo, Marcia Belvin, Jason Boggs et al. · Drug Metabolism and Disposition · 2012 · 35 citations · Full text

SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors

Timothy P. Forsyth, Patrick C. Kearney, Byung Gyu Kim et al. · Bioorganic & Medicinal Chemistry Letters · 2012 · 34 citations · Full text

Medicinal Chemistry, Biochemistry, Vivo Evaluation +9